LISBON, Portugal, Sept. 12, 2011 /PRNewswire/ — Amylin
Pharmaceuticals, Inc. (Nasdaq:
AMLN), Eli Lilly and Company (NYSE:
LLY) and Alkermes, Inc. (Nasdaq:
ALKS) today announced new analyses from the DURATION-3 and -4
trials demonstrating patients treated with the investigational
medication BYDUREON™ (exenatide extended-release for
injectable suspension) experienced significant improvements in
select cardiovascular risk factors, in comparison to patients who
received commonly prescribed diabetes treatments. The analyses
showed that patients receiving BYDUREON for the treatment of type 2
diabetes experienced improvements in composite endpoints related to
body weight, abnormal blood pressure and abnormal lipid levels.
These findings will be presented at the 47th European Association
for the Study of Diabetes Annual Meeting in Lisbon, Portugal.
“Patients with diabetes are at least twice as likely as people
without the disease to have heart disease or a stroke. Having other
chronic conditions including obesity, high blood pressure or high
cholesterol further increases this risk,” said James Malone, MD,
global exenatide medical director, Lilly Diabetes. “These data
underscore the need to consider not only glycemic control but also
the important role played by other medical conditions that are
common among patients with type 2 diabetes.”
Study Results: Patients participating in the DURATION-3 study
received BYDUREON or Lantus® (insulin glargine) in addition to
metformin or metformin plus a sulfonylurea. Interim results from
the study’s ongoing extension found that patients receiving
BYDUREON and completing 84 weeks of therapy:
Demonstrated statistically significant reduction in body weight
(
‘/>”/>
